Source: Virtual Congress 2021 – Acute COVID - 19



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hasegawa (Hamburg, Germany), A. Nakagawa (Kobe, Japan), K. Suzuki (Kobe, Japan), K. Yamashita (Kobe, Japan), S. Yamashita (Kobe, Japan), N. Iwanaga (Kobe, Japan), E. Tamada (Kobe, Japan), K. Noda (Kobe, Japan), K. Tomii (Kobe, Japan). Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19. 3972

Member's Comments

No comment yet.

Related content which might interest you: High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Osteoporosis and inflammation Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Determinants of success Source: Eur Respir J 2011; 38: 1215-1218 Year: 2011 COPD coronary/peripheral vascular disease Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Relationship between lung function impairment and incidence or recurrence of cardiovascular disease in a middle-aged cohort Source: Annual Congress 2007 - Longitudinal and cross sectional risk factors for COPD Year: 2007 Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD) Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Increased injury and intramuscular collagen of the diaphragm in COPD: autopsy observations Source: Eur Respir J 2006; 27: 51-59 Year: 2006 Pertechnegas lung clearance in different forms of interstitial lung disease Source: Eur Respir J 2002; 19: 31-36 Year: 2002 Impact of oxygen supplementation on inflammatory response and muscle lesion during high intensity exercise on chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2006 - Muscles, training and rehabilitation Year: 2006 Different chronic obstructive pulmonary disease phenotypes, systemic inflammation and the risk of falls Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Inadequate glucose control in type 2 diabetes is associated with impaired lung function and with systemic inflammation Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009 Complex chronic comorbidities of COPD Source: Eur Respir J 2008; 31: 204-212 Year: 2008 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 An increased respiratory drive accounts for the severity of dyspnea in systemic sclerosis Source: Annual Congress 2013 –Respiratory muscles at rest and during exercise: from physiology to clinical context Year: 2013